Kinfo
Imac Holdings Inc. logo

Imac Holdings Inc.

BACKNASDAQHealthcare·US · USD
$0.03
+0.00 (+0.00%)
Prices as of July 10, 2026 · market closed

Price

Key statistics

Valuation
Market cap109.76K USD
Enterprise value3.95M USD
Trailing P/E-0.00
Forward P/E-0.01
PEG ratio0.00
Price / sales4.83
Price / book-0.01
Profitability
Gross margin-483.69%
Operating margin-8733.44%
Profit margin-323.66%
Return on assets-550.66%
Return on equity215.99%
Income (TTM)
Revenue22.72K USD
Gross profit-417.84K USD
EBITDA-7.62M USD
Net income-11.57M USD
Diluted EPS-$2.98
Rev. growth (YoY)-62.30%
Balance sheet
Total cash45.05K USD
Total debt3.83M USD
Debt / equity-0.30
Current ratio0.02
Book value / share-$3.43
Cash flow (TTM)
Operating cash flow-4.90M USD
Levered free cash flow-606.81K USD
Shares & price
Shares outstanding3.78M
Float3.72M
Held by institutions0.00%
Beta1.68
50-day MA$0.04
200-day MA$0.07
52-week high$0.21
52-week low$0.02
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-06-173.123.16+1.28%2025-12-12-0.68-2.83−316.18%2025-11-043.163.01−4.75%2025-01-17-0.87-1.38−58.62%2024-12-17-0.44-1.72−290.91%
About Imac Holdings Inc.

IMAC Holdings, Inc. is a clinical research and commercialization company focused on combining life science advancements with traditional medical care across oncology, neurological, and orthopedic specialties. Operating through its subsidiary Ignite Proteomics LLC, the company provides proteomic products and precision medicine services utilizing a patented phosphoprotein and protein biomarker platform. Its reverse phase protein array (RPPA) technology quantifies protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. IMAC Regeneration Centers deliver natural, non-opioid solutions for pain management, addressing demand for conservative treatments in an aging population. The company's laboratory developed tests are utilized by oncologists across the United States to assist in targeted treatment planning for patients with advanced breast cancer. Additionally, IMAC conducts clinical trials for investigational compounds, including umbilical cord-derived allogenic mesenchymal stem cells for neurological conditions. Headquartered in Franklin, Tennessee, IMAC Holdings serves as a bridge between precision diagnostics and personalized medical care in specialized healthcare markets.

Sector
Healthcare
Industry
Medical Care Facilities
CEO
Mr. Jeffrey S. Ervin M.B.A.
Employees
15
Headquarters
Franklin, TN, United States

Frequently asked questions about Imac Holdings Inc.